G-BA Spotlight on Long-Acting Insulin Analogs
This article was originally published in RPM Report
Executive Summary
Novo’s Levemir and Sanofi ’s Lantus get an unwelcome decision from G-BA.
You may also be interested in...
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
What Next In Oncology?
Oncology dominates pharma sales and pipeline league tables. But where is the next Keytruda?